|Bid||53.65 x 28400|
|Ask||53.66 x 2100|
|Day's range||53.42 - 54.48|
|52-week range||46.70 - 67.49|
|Beta (5Y monthly)||1.15|
|PE ratio (TTM)||17.29|
|Earnings date||08 Aug 2023|
|Forward dividend & yield||2.40 (4.42%)|
|Ex-dividend date||02 May 2023|
|1y target est||73.50|
FDA panel votes in favor of Pfizer's (PFE) experimental maternal RSV vaccine. FDA approves AbbVie's (ABBV) Rinvoq for Crohn's Disease.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Bayer's (BAYRY) oral FXIa inhibitor, asundexian, gets the FDA's Fast Track Designation, as a preventive treatment for stroke and systemic embolism in people with atrial fibrillation.
(Reuters) -The U.S. Supreme Court on Monday declined to hear a dispute involving a lawsuit against Bayer AG's Monsanto Co that could rein in a common form of settlement in class action cases under which money is awarded to charities and third parties unrelated to the litigation. The justices turned away an appeal by Anna St. John, an attorney who opposed an agreement for Monsanto to pay more than $39 million to settle claims that the company deceptively labeled certain Roundup weedkiller products. Lower courts rejected the challenge by St. John, who had objected to the settlement because $14 to $16 million of the award would go to consumer non-profit groups and a university that were not injured by the company's alleged misconduct.
Bayer (BAYRY) announces mixed Q1 results. AstraZeneca's (AZN) Ultomiris gets approval for a new rare disease indication in the EU.
Bayer (BAYRY) tops on first-quarter 2023 earnings but misses on sales. Management reiterates guidance.
Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.
It looks like Bayer Aktiengesellschaft ( ETR:BAYN ) is about to go ex-dividend in the next four days. The ex-dividend...
Key Insights Bayer's significant retail investors ownership suggests that the key decisions are influenced by...
Bayer Chairman Norbert Winkeljohann has won backing for his re-election from a pair of major shareholder advisory firms despite criticism from two German investment groups for his numerous board commitments. In separate reports made available to Reuters, Institutional Shareholder Services (ISS) and Glass Lewis said they were backing Winkeljohann when his term comes up for a renewal vote at the drug company's April 28 annual shareholder meeting. German mutual funds groups DWS and Union Investment last month condemned the multiple board commitments of the Bayer chairman, adding to upheaval at the company which is the target of activist investors in the run-up to a change of chief executive on June 1.
Mexico has found unexpected allies as it tries to limit imports of genetically modified (GM) corn: some U.S. farmers who grow the crops. Farmers have for decades planted GM corn, which protects against insects and weedkillers, with seeds sold by companies like Bayer AG, Corteva Inc and ChemChina's Syngenta. But as believers in a free market, some say the U.S. should agree to sell Mexico non-GM corn, rather than deepen a trade dispute over the proposal, and note they could earn a premium for growing more conventional corn.
Incoming Bayer chief executive Bill Anderson says he is keeping an open mind on whether to break up the company into smaller pieces, as some fidgety investors want. Anderson, who takes over the nearly 160-year-old German drugmaker at the start of June after calls from investors to remove his predecessor, says he will spend the next two months "listening" and sees no consensus on the issue so far. The 56-year-old chemicals engineer from the U.S., brought over from Swiss rival Roche, begins at a testing time, weighed down by lawsuits claiming Bayer's weed-killer causes cancer and pressure from investors demanding major change.
(Reuters) -A Delaware judge on Monday dismissed Merck & Co's lawsuit seeking to hold Bayer AG responsible for more talc-related liabilities stemming from its $14.2 billion purchase of Merck's consumer care business in 2014. Vice Chancellor Nathan Cook of the Delaware Chancery Court said the purchase agreement "clearly and unambiguously" left Merck liable for claims related to products, including Dr. Scholl's foot powder, sold before the transaction closed. Merck claimed that its liability ended on Oct. 1, 2021, seven years after the transaction closed, and sued Bayer after the German company refused to assume liability.
The European Union's decision to postpone rule changes for the pharmaceutical industry could open the way for a rethink of a decision to cut intellectual drug property protection, the head of Bayer's pharmaceuticals division said. The European Commission said this week that the publication of a first draft of a planned revision of drug legislation in the bloc would be "slightly later" than March 29, as initially planned. A version that was leaked earlier this year showed that Brussels was preparing to shorten an additional period of intellectual property protection, known as data exclusivity, which comes on top of drug patent protection.
Bayer AG plans to spend $1 billion on drug research and development in the U.S. this year as it works to double its sales in the country by the end of the decade, Bayer's top U.S. pharmaceutical executive told Reuters. Sebastian Guth, president of Bayer's pharmaceuticals business in the Americas, also said in an interview on Wednesday that the company had raised the number of U.S. employees working on marketing for its pharmaceutical business by around 50% over the last three years, and plans to expand on that by another 75% by 2030. "It's time for us to double down on the U.S.," Guth said, noting that Bayer plans to sell the drugs it is developing itself in the country, rather than partner with U.S. companies like it has in the past.
Nearly all corn and soybean acres in the world's largest exporting countries are seeded with genetically modified varieties, but that is not the case for wheat, a crop grown primarily for human food. Biotech varieties of corn and soy, used for animal feed, biofuels and ingredients like cooking oil, were introduced in 1996 and soon came to dominate plantings in the United States as well as Brazil and Argentina, the world's top suppliers. But genetically modified wheat has never been grown for commercial purposes due to consumer fears that allergens or toxicities could emerge in a staple used worldwide for bread, pasta and pastries.
When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") above 16x, you may consider...
Bayer (BAYRY) beats on earnings and sales in the fourth quarter. However, its 2023 outlook is dismal.
FRANKFURT (Reuters) -Bayer warned operating earnings would decline in 2023, adding to the challenges for its new CEO who will take the helm in June, as the agriculture and healthcare company is hit by higher costs and the reversal of last year's price boost for its weedkillers. Bayer said in a statement that earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for special items, would likely be between 12.5 billion euros and 13 billion euros ($13.2 billion - $13.8 billion) this year, excluding the effect of currency swings. Chief Executive Werner Baumann, who is scheduled to quit at the end of May, defended the company's presence in agriculture and healthcare.
FRANKFURT (Reuters) -Bayer has appointed Jeff Ubben to the drugmaker's independent sustainability council, in a sign that the activist investor will be given a say at the embattled group. The Germany company said in a statement on Monday that Ubben would be one of three new entrants to the nine-member council, which meets with members of Bayer's management board twice a year. Bayer's shares have been weighed down by litigation over its Roundup weedkiller and by its diversified structure, drawing investors' criticism.
Germany's Bayer has been ordered by Brazil's Supreme Court to return to Brazilian soybean farmers the royalties they were charged for a GMO soybean seed, the Mato Grosso farmer lobby Aprosoja-MT said in a statement on Friday. The Feb. 13 ruling by Supreme Court Justice Nunes Marques relates to a GMO technology commercially known as Intacta RR2 Pro, created by Monsanto, which was later acquired by Germany's Bayer.
AstraZeneca (AZN) and AbbVie (ABBV) report fourth-quarter results. Roche (RHHBY) and J&J (JNJ) announce positive data from studies on pipeline candidates for rare diseases.
Regeneron's (REGN) Eylea gets FDA approval for the treatment of preterm infants with retinopathy of prematurity (ROP).
Bayer's incoming CEO is inheriting a full in-tray from his predecessor: Thousands of lawsuits claiming its weedkiller causes cancer, an underwhelming drug development pipeline and disgruntled investors looking for major change. Top investors, including mutual funds group Deka, are among those to have complained that Bayer's sagging shares have been burdened by a lack of trust in the company's leadership, with others reckoning one easy fix would be to separate the healthcare and agricultural businesses. Bayer on Wednesday named long-time Roche executive Bill Anderson for the top job after months of shareholder pressure to remove embattled CEO Werner Baumann, who had previously said he would hold on until the end of his current term in April 2024.